Table 1 Summary of statistical tests of null changes between baseline and 52 weeks and tests of null differences at baseline using all detected molecules in CSF of patients treated with placebo (N = 19) or resveratrol (N = 19)

Aβ40

0.0031**

0.0014**

0.0784

0.0066**

0.0029**

0.3579

0.3587

0.5284

Aβ42

0.0112*

0.0027**

0.0784

0.0105*

0.0034**

0.3764

0.3739

0.4986

pTau 181

0.0665

0.6498

0.4409

0.0649

0.2891

0.7043

0.7044

0.9319

tTau

0.91

0.3673

0.4614

0.9622

0.2163

0.5769

0.5638

0.9373

MMP-9

0.0474*

0.0027**

0.0241*

0.0771

0.0034**

0.8751

0.8737

1.0000

MMP-3

0.6098

0.5437

0.942

0.5016

0.6848

0.6911

0.6882

0.9311

MMP-2

0.5781

0.2322

0.9759

0.7049

0.3388

0.8828

0.8828

0.8509

MMP-10

0.4965

0.3175

0.9999

0.9341

0.5935

0.9415

0.9410

0.6807

FGF-2

0.3676

0.0248*

0.269

0.2128

0.0273*

0.6751

0.6774

0.5508

TGFα

0.8693

0.0829

0.4257

0.61

0.2324

0.5571

0.5519

0.9843

G-CSF

0.0532

0.1196

0.6722

0.0942

0.1563

0.2042

0.2422

0.4195

MCP-3

0.4751

0.0802

0.2922

0.5625

0.1094

0.2366

0.2305

0.2948

MDC

0.8121

0.001***

0.0505

0.8938

0.0009***

0.0458

0.0566

0.0678

PDGF-AA

0.9866

0.1106

0.0728

0.804

0.0787

0.9883

0.9886

0.8957

IL-4

0.9647

0.0085**

0.1828

0.6875

0.0167*

0.0860

0.0992

0.0748

PDGF-AB/BB

0.1752

0.4337

0.3356

0.0463*

0.057

0.6349

0.6261

0.7881

IL-8

0.262

0.1177

0.1594

0.57

0.0465*

0.9648

0.9648

0.6450

Flt-3L

0.9602

0.1132

0.5639

0.8498

0.155

0.8880

0.8880

0.8109

Fractalkine

0.791

0.4409

0.5973

0.6701

0.9382

0.4541

0.4543

0.8641

IFNα2

0.8832

0.4182

0.2943

0.8361

0.7547

0.8727

0.8729

0.6194

IL-15

0.9469

0.3587

0.3867

0.816

0.4263

0.7049

0.7029

0.6813

IL-7

0.8148

0.4458

0.3147

0.8384

1

0.4650

0.4553

0.4305

IP-10

0.2769

0.4091

0.405

0.6026

0.7368

0.3900

0.3918

0.8509

MCP-1

0.8089

0.5809

0.7419

0.421

0.8971

0.8650

0.8650

0.9864

MIP-1b

0.3973

0.2909

0.6174

0.3621

0.2188

0.7722

0.7632

0.8401